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ABSTRACT
Although sulfidopeptide leukotrienes (sLT) are consid-
ered to play an important role in the pathogenesis of
asthma, their precise action has not been elucidated in
asthmatics during exacerbation. In the present study,
we examined sputum concentrations of sLT from asth-
matic patients in order to determine whether sLT are
actively involved in the exacerbation of asthma. We
also examined sputum levels of thromboxane (TX) B2
and histamine because these mediators are consid-
ered to be as important as sLT. The induced sputa by
3% hypertonic saline inhalation were treated with
high-performance liquid chromatography and levels
of sLT, TXB2 and histamine were measured with enzyme
immunoassay kits. These compounds tended to be 
elevated in asymptomatic asthmatic patients com-
pared with healthy controls, but the differences were
not significant. Levels of sLT and TXB2 showed no 
difference between atopic and non-atopic patients, 
but histamine levels were higher in atopic patients than
in non-atopic patients. However, sputa during the
exacerbation contained significantly higher levels of
sLT than those during the asymptomatic state. In con-
trast, neither histamine nor TXB2 showed any changes
with exacerbation. These results suggest that sLT may
be one of the most potent for mounting the exacerba-
tion of asthma.
Key words: asthma, histamine, sputum, sulfido-
peptide leukotrienes, thromboxane B2.
INTRODUCTION
Recently, it has been established that allergic inflamma-
tion is the most important in the pathogenesis of asthma.
Many investigators have been analyzing the inflammatory
status of airways in asthmatics using techniques such as
bronchoalveolar lavage (BAL) and transbronchial lung
biopsy (TBLB). However, because these methods are inva-
sive, they are hardly repeated or performed during the
exacerbation of asthma. Analysis of sputum is a well-
established and commonly used technique for evaluating
asthmatics.1 Mediators and albumin levels were found to
be higher in induced sputum compared with BAL fluid.
However, mediators and albumin levels in sputum were
closely correlated with those in BAL. In addition, the
analysis of induced sputum revealed information qualita-
tively similar to that obtained by analysis of BAL.2 Finally,
many inflammatory cytokines have been measured in
sputum from asthmatic patients.3
It is well known that leukotrienes (LT) are potent inflam-
matory mediators, producing acute bronchoconstriction
and airway hyperresponsiveness to methacholine or 
histamine.4–7 Increased numbers of eosinophils and
neutrophils in the airway mucosa have been reported
after the inhalation of LTE48 or LTD4.9 However, analyses
of these potent inflammatory mediators, sulfidopeptide-
leukotrienes (sLT) such as LTC4, LTD4 and LTE4, have been
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rarely performed in the sputum, partly because these lipid
mediators are unstable and are rapidly metabolized,
making their measurement difficult. These lipid mediators
may serve as markers reflecting the clinical condition of
asthma. We have examined expired nitric oxide (NO)
from airways10 and eosinophil cationic protein (ECP) in
the peripheral blood as markers of airway inflammation
in asthmatic patients, but none showed a relationship
with asthma symptoms. Pranlukast, a new sLT receptor
antagonist, has been reported to be remarkably effective
in improving the mean peak expiratory flow rate (PEFR),
forced expiratory volume in 1 s (FEV1), and symptom
score in a randomized double-blind placebo-controlled
multicenter study in Japan,11 Europe12 and the US.13
Therefore, we suspect that sLT are important mediators of
asthma, affecting the severity of inflammation and airway
hyperreactivity. Accordingly, we examined sLT levels in
sputum obtained from asthmatic patients during exacer-
bation and asymptomatic status, as well as from healthy
controls. Because it has been shown that seratrodast, a
thromboxane (TX) A2 receptor antagonist, could improve
asthmatic symptoms,14 we also investigated concentrations
of TXB2, a metabolite of TXA2, and histamine in sputum.
METHODS
Subjects
Sixty-six patients with asthma and 12 healthy subjects
were enrolled in this study (Table 1). Asthmatic patients
were diagnosed on the basis of evidence of reversible
airway obstruction and airway hypersensitivity and were
treated in the Department of Allergy, National Minamio-
kayama Hospital. Healthy controls who participated in
this study had no history of pulmonary, cardiovascular or
nasal disorders. All subjects were non-smokers. Informed
consent was obtained from all patients and healthy 
controls and the study was approved by the institutional
review board.
Patients enrolled in this study were in a stable condi-
tion, with neither dyspnea nor wheeze. In some patients,
sputa were also collected during exacerbation. Exacer-
bation was defined as a condition with symptoms,
wheeze and dyspnea or 20% decrease of PEFR.
The mean (±SD) age of asthmatic patients was
50.3 ± 15.7 years, similar to controls, who were aged
46.8 ± 11.8 years. Of the asthmatic patients, 37 were
atopic (20 male and 17 female; mean age 45.5 ± 16.7
years) and 29 were non-atopic (11 male and 18 female;
mean age 56.1 ± 12.1 years). Thirteen atopic patients
had mild disease, 18 had moderate disease and six 
had severe disease. One of the non-atopic asthmatics had
mild disease, nine had moderate disease and 19 had
severe disease. Patients who had allergic rhinitis, atopic
dermatitis, allergic family history or high IgE antibody titer
were considered atopic, while non-atopic patients were
considered as those who had none of the above charac-
teristics. The grade of severity was determined according
to the Japanese Guideline for Asthma.15
The majority of patients were on regular inhalation of
beclomethasone dipropionate (300–1800 µg/day; 22
and 26 atopic and non-atopic patients, respectively) or
oral administration of prednisolone (3–15 mg/day; five
and 15 atopic and non-atopic patients, respectively) and
theophylline or β2-adrenoceptor agonists. The remain-
ing patients were maintained on theophylline or β2-
adrenoceptor agonists without steroids (15 in the atopic
and three in the non-atopic group).
Collection of sputum
Sputum was induced by inhalation of hypertonic saline
(3%) according to established methods.1,2 The reservoir
of a nebulizer (Nebulizer Type A; Nissho, Osaka, Japan)
was filled with 10 mL sterile 3% saline. After rinsing the
mouth with water to avoid saliva contamination, each
subject inhaled the nebulized solution for 30 min.
Subjects were encouraged to cough throughout the pro-
cedure as needed, at least every 10 min, and the sputum
was collected into clean plastic containers. If the sputum
volume was insufficient after 30 min collection, 5% saline
was inhaled for an additional 20 min. Further inhalation
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Table 1 Characteristics of the subjects studied
Asthmatics Normal
subjects
No. cases (male/female) 66 (31/35) 12 (10/2)
Age (years) 50.3 ± 15.7 46.8 ± 11.8
Type
Atopic
No. cases 37
Age (years) 45.5 ± 16.7
Non-atopic
No. cases 29
Age (years) 56.1 ± 12.1
Lung function
%VC 100.4 ± 21.7
%FEV1 67.5 ± 10.6
VC, vital capacity; FEV1, forced expiratory volume in 1 s.
was stopped even if the quantity of the collected sputum
was still unsatisfactory. The volume of the collected
sputum was recorded and immediately stored on ice to
stop the metabolism of lipid mediators. Stopping enzyme
was not used in this study because our method to analyze
sLT, described later, was designed to measure both LTC4
and its metabolites. A 1 mL sputum sample was diluted
four-fold with ethanol and stored at –80°C for analysis of
sLT and TXB2. Another 1 mL sputum was diluted three-
fold with isotonic saline and stored at –80°C for
histamine assay. A small amount of the remainder was
taken for preparing a May–Grunwald–Giemsa stained
smear for the cell differential.
Analysis of LT and TX
Analysis of sLT and TXB2 was performed according to the
modified three-stage procedure (purification, separation
and quantitation), as described previously.16–18 Briefly, the
sample was centrifuged at 1500 g for 10 min at 4°C to
remove debris and precipitated protein and the super-
natant was collected. After evaporation in a vacuum, 
the supernatant was reconstituted with 6 mL methanol
and purified on C18 Sep-Pak cartridges (Waters Co.,
Massachusetts, USA). Leukotriene- and TX-containing
materials were eluted in methanol, evaporated to dryness
and stored at –80°C for application to reverse-phase
high-performance liquid chromatography (HPLC; SCL-
10A; Shimazu, Kyoto, Japan). The HPLC was performed
using 5 µm C18 analytical and guard columns with 
a mobile phase (47% acetonitrile with 1 mmol/L sodium
1-octanesulfonate and 2 mmol/L KH2PO4 and 3.38 mg/
mL phosphoric acid) at a flow rate of 1 mL/min. Using a
fraction collector (FCR-10A; Shimazu), separation and
collection of LTC4, LTD4, LTE4 and TXB2 was undertaken.
Measurements of sLT were performed using whole 
fractions of LTC4, LTD4 and LTE4 with a Peptide–
Leukotriene EIA KIT (Cayman Chemical, Ann Arbor, MI,
USA). We did not measure each fraction of LTC4, LTD4
and LTE4 because LTC4 is rapidly metabolized to LTD4.
TXB2 was measured in collected TXB2 fractions with an 
EIA Kit (Cayman Chemical). The recovery rates of these
lipid mediators were between 75 and 80%. Results are
expressed in ng/mL of sputum and were corrected by the
quantity of albumin in the sputum.
Analysis of histamine
Analysis of histamine was performed as reported
recently.3 The diluted sputum was homogenized for
10 min at room temperature. After centrifugation at
75 000 g for 30 min at 4°C, the supernatant was col-
lected and stored at –80°C until measurement with an
EIA Kit (Immunotech, Marseilles, France). Results were
corrected by albumin concentration in the sputum and
expressed in nmol/L. Albumin was measured in the hista-
mine supernatant using a COBAS MIRA analyzer (Roche
Diagnostic, Tokyo, Japan).
Statistical analysis
Data are expressed as the geometric mean ± geometric
SD. Data were statistically analyzed by analysis of vari-
ance (ANOVA) using STAT IST ICA (StatSoft JAPAN, Tokyo,
Japan). A probability of 5% or less was considered statis-
tically significant.
RESULTS
Sputum cell differentials
For cell differentials, we subtracted the number of squa-
mous cells from the number of whole cells in the sputum
and counted 500 cells, because squamous cells in the
sputum sample represented salivary contamination. As
shown in Fig. 1, the corrected cell differentials showed a
significantly higher percentage of eosinophils (P < 0.02)
in all sputum samples from asthmatic patients
(10.02 ± 8.16%) compared with those from normal sub-
jects (0.28 ± 0.49%). The percentage of eosinophils in
the sputum was significantly higher in asthmatics during
exacerbation (11.44 ± 10.11%; P < 0.01) and also in
asymptomatic asthmatics (8.66 ± 5.65%; P < 0.02)
compared with that in normal controls. However, there
was no significant difference in the percentage of other
cell types in exacerbated and asymptomatic patients
compared with normal controls in the present study.
Sulfidepeptide–leukotriene, thromboxane and
histamine
We compared the concentrations of sLT (Fig. 2a) in the
sputum from asymptomatic asthmatics and normal con-
trols (1.02 ± 1.93 and 0.43 ± 0.30 ng/mL, respectively)
and there was no significant difference. Concentrations
of TXB2 (Fig. 2b) in the sputum showed a similar ten-
dency in asymptomatic asthmatics and normal controls
(1.11 ± 2.65 and 0.27 ± 0.17 ng/mL, respectively)
and there was no significant difference between the 
two groups. Histamine concentrations (Fig. 2c) in the
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Fig. 1 Differential cell count in sputum from normal subjects () and asthmatics (, asymptomatic; , during exacerbation). The
percentage of eosinophils was increased in asthmatics with or without exacerbation compared with normal subjects. Eosinophils
were further increased during exacerbation. No significant difference was observed in macrophages, lymphocytes or neutrophils.
Fig. 2 Concentrations of (a) sulfidopeptide leukotrienes (sLT), (b) thromboxane (TX) B2 and (c) histamine in sputum from normal
subjects (n = 12) and asthmatics without symptoms (n = 53). Measurements were performed several times in asthmatics. The sLT
levels in sputum from asthmatics without symptoms were not significantly higher than those in normal controls. Levels of TXB2 showed
no significant difference. Histamine levels showed a significant increase in asthmatics. Symbols indicate individual data points, while
the bars are the mean ± SD.
sputum from asthmatics (85.64 ± 44.81 nmol/L) were
significantly higher compared with normal controls
(21.47 ± 15.45 nmol/L; P < 0.002).
We then compared these mediators between atopic
and non-atopic patients. The sLT levels (Fig. 3a) in the
sputum from atopic and non-atopic patients were
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Fig. 3 Comparisons of (a) sulfidopeptide leukotrienes (sLT), (b) thromboxane (TX) B2 and (c) histamine levels  in sputum between
atopic (n = 37) and non-atopic (n = 29) patients. Only histamine levels showed a significant difference and were higher in atopic
than in non-atopic subjects (P < 0.001). 
Fig. 4 Comparison of (a) sulfidopeptide leukotrienes (sLT), (b) thromboxane (TX) B2 and (c) histamine levels in sputum according to
severity of asthma. Levels of sLT and TXB2 in the sputum showed no significant difference. However, histamine levels in sputum showed
a significant decrease in severe cases compared with moderate cases (P < 0.0001). Data are the mean ± SD, NS, not significant.
0.86 ± 0.87 and 1.26 ± 2.91 ng/mL, respectively.
There was no significant difference between these two
groups. As for TXB2 levels (Fig. 3b), similar results were
obtained with 0.81 ± 1.52 and 1.55 ± 3.78 ng/mL in
the atopic and non-atopic groups, respectively. However,
histamine concentrations were significantly higher in the
atopic group (101.03 ± 42.44 nmol/L) compared with
the non-atopic group (54.87 ± 33.18 nmol/L), as shown
in Fig. 3c (P < 0.001).
These mediators in the sputum were also evaluated
according to the severity of asthma (mild, moderate, or
severe). The sLT levels were 0.98 ± 0.89 ng/mL in the
mild group, 1.55 ± 2.95 ng/mL in the moderate group
and 0.53 ± 0.35 ng/mL in the severe group. Differences
were not significant among these three groups (Fig. 4a).
In addition, there was no significant difference in TXB2
levels among the mild (0.54 ± 0.61 ng/mL), moderate
(1.26 ± 1.95 ng/mL) and severe (1.22 ± 3.66 ng/mL)
groups (Fig. 4b). In contrast, there was a significant 
difference in histamine levels (Fig. 4c) only between 
the moderate (112.03 ± 27.70 nmol/L) and severe
(50.25 ± 32.75 nmol/L) groups (P < 0.0001).
There was no difference in sLT levels between normal
subjects and asthmatics without symptoms. We then
investigated sLT levels within the same individual asth-
matics when their pulmonary functions were stable com-
pared with acute exacerbation (20% decrease in PEFR
with wheeze and dyspnea). As shown in Fig. 5a, sLT levels
were significantly elevated during exacerbation (2.78 ±
1.78 ng/mL; P < 0.0001) compared with those obtained
when patients were asymptomatic (0.88 ± 0.83 ng/mL).
However, TXB2 levels did not change in association with
exacerbation (1.00 ± 1.06 ng/mL) compared with the
stable state (1.19 ± 1.85 ng/mL; Fig. 5b). Histamine
levels also did not show any change with exacerbation
(Fig. 5c; 76.87 ± 48.40 ng/mL with exacerbation vs
80.46 ± 41.10 ng/mL in the stable state).
DISCUSSION
Research into airway inflammation using sputum has
been established and there are many reports using 
this technique. Fahy et al. have shown changes in the 
type and quantity of inflammatory cells in sputum fol-
lowing inhalation of hypertonic saline after an allergen
challenge.19,20
In this study, using these established methods with
sputum, we demonstrated an elevated level of sLT in the
sputum during exacerbation of asthma. In contrast, TXB2
and histamine were not elevated during exacerbation of
asthma. These results suggest that sLT may play a more
important role in worsening symptoms of asthma com-
pared with TX and histamine. However, these results do
not directly indicate that sLT are the most important
factors in allergic inflammation in the airway, because sLT
were not significantly elevated in the stable state, the 
condition in which allergic inflammation was still present.
It is known that inflammatory cells in the airway can
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Fig. 5 Comparisons of (a) sulfidopeptide leukotrienes (sLT), (b) thromboxane (TX) B2 and (c) histamine levels in the sputum of
asymptomatic asthmatics compared with the exacerbation state. Levels of sLT were elevated in exacerbation (P < 0.0001). However,
TXB2 and histamine levels showed no significant change. Data are the mean ± SD.
produce LTs.21 We have previously reported elevated
levels of LTC4 and LTB4 in BAL fluid in the late asthmatic
response following inhalation of house dust allergen.22
In addition, increased LTC4 levels in BAL fluid from
atopic asthmatics after allergen challenge have been
reported.23 In contrast, sLT receptor antagonists, such as
pranlukast, montelukast and zafirlukast, have been shown
to improve FEV1 in patients with chronic persistent
asthma,24 to inhibit allergen-induced bronchoconstriction,25
to produce marked clinical effects12,26 and to prevent
airway obstruction induced by lysine–aspirin in aspirin-
sensitive asthmatics.27 Our results and the results of these
reports suggest that sLT may play a more important role
in the acute asthmatic reaction, such as an exacerbation,
and after antigen challenge than in the stable persistent
inflammatory state. In contrast, TX may play a more effec-
tive role compared with sLT in baseline bronchial
hyperresponsiveness. Some reports have shown that the
TXA2 receptor antagonist seratrodast was effective in
asthmatics14 and that 4 days administration of seratrodast
at 40 mg/day reduced bronchial hyper-responsiveness in
patients with asthma.28 In contrast, a few reports have
shown that sLT attenuates baseline bronchial hyper-
responsiveness.29,30
In this study, only sLT levels, not TXB2 or histamine
levels, in the sputum were elevated during exacerbation
compared with asymptomatic disease. There are several
possible explanations for this increase in sLT. First, sLT are
formed by 5-lipoxygenase (5-LO), while TX is produced
by cyclo-oxygenase. Because the synthesizing enzymes
are different, sLT and TX may be not always be produced
in parallel; indeed, not only a decrease in sLT but also an
increase in TX in BAL fluid was observed after administra-
tion of the 5-LO inhibitor zileuton.31 Another possible
explanation, as mentioned before, is that sLT are more
important factors in the acute asthmatic reaction com-
pared with baseline inflammation, while TX may be more
involved in baseline allergic inflammation.14,28 Another
explanation is that a process progressing to exacerbation
may be variable depending on individual asthmatics. For
example, sLT may be the main factor in one patient, while
TXB2 may be important in another. Indeed, cases in whom
sLT levels in the sputum were low and TXB2 levels were
high and cases with high sLT levels and low TXB2 levels
were observed in our study.
Histamine concentrations were significantly higher in
atopic patients. Histamine is known to be an important
factor in atopic disorders. However, sLT and TXB2 levels
were not different in atopic and non-atopic patients. It is
not surprising that sLT and TX do not relate to atopic reac-
tions because mast cells predominate in this reaction. In
contrast, sLT and TX are supposed to play roles in
eosinophil inflammation. Another significant change, the
lower histamine level in patients with severe disease, may
be explained by frequent administration of corticosteroids
in such patients. However, corticosteroids may also
decrease the levels of sLT and TXB2. It is possible that 
corticosteroids only control increased sLT and TXB2 levels
to normal range.
In conclusion, our results suggest that sLT contribute to
the pathogenesis of asthma or, at least, that sLT exacer-
bate asthma more potently than histamine and TXA2. This
fact explains why sLT receptor antagonists can reduce
asthma symptoms and improve PEF and FEV1, while 
histamine receptor antagonists do not.
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